Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887284 | 0.91 | MAPT (0.40) | LMNAGAAMAPTTP53POLB | |
| SCHEMBL5887418 | 0.90 | LMNA (0.39) | LMNAGAAMAPTTP53POLB | |
| SCHEMBL5887173 | 0.90 | LMNA (0.39) | EPHX2LMNARORCGAAMAPT | |
| SCHEMBL5887414 | 0.87 | CCR1 (0.43) | CCR1EPHX2NR1H4LMNAMAPT | |
| SCHEMBL5887478 | 0.86 | POLB (0.42) | GAAMAPTTP53POLBALDH1A1 | |
| SCHEMBL5887581 | 0.85 | KLKB1 (0.38) | LMNA | |
| SCHEMBL5887547 | 0.85 | PRKAB2 (0.41) | CCR1EPHX2NR1H4LMNARORC | |
| SCHEMBL5887403 | 0.82 | PDE4B (0.39) | CNR1CNR2POLB | |
| SCHEMBL5886833 | 0.82 | CCR1 (0.43) | CCR1EPHX2NR1H4LMNARORC | |
| SCHEMBL5886848 | 0.82 | CCR1 (0.43) | CCR1EPHX2NR1H4LMNARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | CCR1 4456/4885EPHX2 2968/4885NR1H4 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.